A tale of two antiviral targets — and the COVID-19 drugs that bind them

@article{Cully2021ATO,
  title={A tale of two antiviral targets — and the COVID-19 drugs that bind them},
  author={Megan Cully},
  journal={Nature Reviews Drug Discovery},
  year={2021},
  volume={21},
  pages={3-5}
}
  • Megan Cully
  • Published 2 December 2021
  • History
  • Nature Reviews Drug Discovery
The FDA is considering authorizations for Pfizer’s paxlovid and Merck & Co.’s molnupiravir, the first two oral COVID-19 antivirals. The FDA is considering authorizations for Pfizer’s paxlovid and Merck & Co.’s molnupiravir, the first two oral COVID-19 antivirals. 
The Role of Oral Antivirals for COVID-19 Treatment in Shaping the Pandemic Landscape
Several vaccines against coronavirus disease 2019 (COVID-19) were developed and made available in a record time, just over a year after the outbreak of severe acute respiratory syndrome coronavirus 2
An Overview of Marketed Nucleoside and Nucleotide Analogs
TLDR
An overview of the nucleos(t)ide analogs that have received marketing approval is given, including antiviral and antitumoral nucleosid analogs as well as nucleosides that have receiving marketing approval in other therapeutic areas.
Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication
TLDR
The antiviral activity profile of probenecid against the most common respiratory viruses are endemic agents such as coronaviruses, respiratory syncytial viruses, and influenza viruses.
Defining the Substrate Envelope of SARS-CoV-2 Main Protease to Predict and Avoid Drug Resistance
TLDR
The substrate envelope of Mpro is defined by determining the molecular basis of substrate recognition, through nine high-resolution cocrystal structures of SARS-CoV-2 Mpro with the viral cleavage sites, to enable identification of evolutionarily vulnerable sites beyond the substrate envelope that may be susceptible to drug resistance and compromise binding of the newly developed Mpro inhibitors.
Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir
Dual Inhibition of Cathepsin L and 3CL-Pro by GC-376 Constrains SARS Cov2 Infection Including Omicron Variant
TLDR
It is reported that cathepsin-L and 3CL-Pro as major targets for designing antivirals against SARS CoV2, and early evidence that 3 CL-Pro inhibition can effectively inhibit omicron-induced CPE in highly susceptible cell lines suggests that the recently FDA-approved oral drug could be effective against omicrons variant which shows reduced sensitivity to vaccines and mAb.
Effective Reduction of SARS-CoV-2 RNA Levels Using a Tailor-Made Oligonucleotide-Based RNA Inhibitor
TLDR
This work reports on a specific oligonucleotide-based RNA inhibitor targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which displayed remarkable spontaneous cellular uptake, and efficiency in reducing RNA-dependent RNA polymerase (RdRp) RNA levels in transfected lung cell lines.
Recent Advances in Influenza, HIV and SARS-CoV-2 Infection Prevention and Drug Treatment—The Need for Precision Medicine
TLDR
The views on vaccination and pharmacotherapy, their mutually reinforcing strategic significance in combating pandemics, and the pros and cons of host and virus-targeted drug therapy are shared.
Omicron: Understanding the Latest Variant of SARS‐CoV‐2 and Strategies for Tackling the Infection
Abstract The new variant of concern of SARS‐CoV‐2, namely Omicron, has triggered global fear recently. To date, our knowledge of Omicron, particularly of how S glycoprotein mutations affect the
...
1
2
...